BME100 f2013:W900 Group1 L2
|BME 100 Fall 2013|| Home |
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Wiki Editing Help
LAB 2 WRITE-UP
Inflammotin in Different Dosages of LPS in Humans
Inflammotin in two Dosages of LPS in Rats
This graph shows the correlation between four different dosages 0mg, 5mg, 10 mg and 15mg of lipopolysaccharides(LPS) and the levels inflammotin(pg/ml) in humans. In addition, this graph shows that the averages and standard diviation of inflammotin are a lot different from one another.
This graph shows the correlation between two different dosages 0mg and 10mg of lipopolysaccharides(LPS) and the levels inflammotin in rats. Furthermore, this graph shows that the averages of inflammotin are not much different from one another; however, there is a difference in the standard deviation of the information.
The result of the T-test does show a correlation between the two sample means, but not at a very statistically significant level. This may be due to the very small sample size for the rat study.
The goal for both experiment 1 and experiment 2 is to try and raise the level of inflammotin within the subjects we were testing by using a new treatment that uses lipopolysaccharides, or LPS for short. In experiment number 1, the test subjects were humans over the age of 60, with the average age being 64.6 years old. The subjects were broken down into groups of ten and each group was given a different dose of LPS ranging from 0 milligrams, as a control group, to 15 milligrams in intervals of 5. This lead to widely varying levels of inflammotin in each group. The average level of inflammotin for the control group that received 0 milligrams was 3.834 with a standard deviation of 1.523010177 and standard error of 0.481618106. The results do not vary widely from 0 milligrams to 5 milligrams but do show significant increases from 5 milligrams to 10 milligrams. The average level of inflammotin at 10 milligrams was 61.662 while the standard deviation was 30.11069386 and the standard error was 9.521837451. This dosage shows a significant increase of inflammotin and in the deviation and error. This can be attributed to both the difference in the ages of the people within the group and the way their own bodies reacted to the dosage. This can cause error in the experiment but also shows what dosage gives a large increase in the amount of inflammotin in the blood stream. The 15 milligram dosage showed an even higher spike in inflammotin levels than 10 milligrams did. The average level of inflammotin at 15 milligrams was 657.941 with a standard deviation of 212.9429762 and standard error of 67.33848166. This high deviation again can be attributed to different biological factors within each subject and their age, as the older test subjects experienced more inflammotin in the body than the younger subjects. From this we can conclude that if the inflammotin level needs to be brought up significantly, 15 milligrams can do it, but if a much smaller level is needed, then a dosage of 10 milligrams can work fine with a much smaller window for error and deviation. The second test had much different results and was handled much differently than the first. In this test only a control receiving 0 milligrams and a group receiving 10 milligrams were used. The other difference in this test is that rats were used instead of people. This test showed us that the rats were not affected substantially by the dosage like the humans were, with the control group already having an average level of 10.516 of inflammotin in the bloodstream and the group receiving a dosage of 10 only going up to an average of 11.112 with a higher standard deviation and error. This test does not help the study profoundly, as the rats proved to be unaffected by the doses, however, the test was run with less use of less doses than the human test and further testing is may be necessary.